SG11201402609RA - Compositions and methods for treating hepatitis c virus - Google Patents

Compositions and methods for treating hepatitis c virus

Info

Publication number
SG11201402609RA
SG11201402609RA SG11201402609RA SG11201402609RA SG11201402609RA SG 11201402609R A SG11201402609R A SG 11201402609RA SG 11201402609R A SG11201402609R A SG 11201402609RA SG 11201402609R A SG11201402609R A SG 11201402609RA SG 11201402609R A SG11201402609R A SG 11201402609RA
Authority
SG
Singapore
Prior art keywords
virus
compositions
methods
treating hepatitis
hepatitis
Prior art date
Application number
SG11201402609RA
Other languages
English (en)
Inventor
Darryl G Cleary
Charles J Reynolds
Miriam Michelle Berrey
Robert G Hindes
William T Symonds
Adrian S Ray
Hongmei Mo
Christy M Hebner
Reza Oliyai
Vahid Zia
Dimitrios Stefanidis
Rowchanak Pakdaman
Melissa Jean Casteel
Original Assignee
Gilead Pharmasset Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56291296&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201402609R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2012/055621 external-priority patent/WO2013040492A2/en
Priority claimed from US13/661,509 external-priority patent/US20130109647A1/en
Application filed by Gilead Pharmasset Llc filed Critical Gilead Pharmasset Llc
Publication of SG11201402609RA publication Critical patent/SG11201402609RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11201402609RA 2011-11-29 2012-11-27 Compositions and methods for treating hepatitis c virus SG11201402609RA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161564500P 2011-11-29 2011-11-29
PCT/US2012/055621 WO2013040492A2 (en) 2011-09-16 2012-09-14 Methods for treating hcv
US201261707459P 2012-09-28 2012-09-28
US13/661,509 US20130109647A1 (en) 2011-10-31 2012-10-26 Methods and compositions for treating hepatitis c virus
PCT/US2012/066605 WO2013082003A1 (en) 2011-11-29 2012-11-27 Compositions and methods for treating hepatitis c virus

Publications (1)

Publication Number Publication Date
SG11201402609RA true SG11201402609RA (en) 2014-06-27

Family

ID=56291296

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201402609RA SG11201402609RA (en) 2011-11-29 2012-11-27 Compositions and methods for treating hepatitis c virus

Country Status (22)

Country Link
EP (2) EP3777867A1 (hr)
JP (2) JP5899327B2 (hr)
KR (1) KR101560994B1 (hr)
CN (1) CN104039319B (hr)
AR (1) AR089578A1 (hr)
AU (1) AU2012346217B2 (hr)
BR (1) BR112014012739A8 (hr)
CA (1) CA2856529C (hr)
CO (1) CO6970603A2 (hr)
EA (1) EA027296B1 (hr)
EC (1) ECSP14005678A (hr)
ES (1) ES2817886T3 (hr)
HK (1) HK1202268A1 (hr)
MD (1) MD4430C1 (hr)
MX (1) MX2014006373A (hr)
PE (1) PE20141296A1 (hr)
PH (1) PH12014501133B1 (hr)
SG (1) SG11201402609RA (hr)
TW (1) TWI566773B (hr)
UY (1) UY34474A (hr)
WO (1) WO2013082003A1 (hr)
ZA (1) ZA201404061B (hr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104244945B (zh) 2011-09-16 2016-08-31 吉利德制药有限责任公司 用于治疗hcv的方法
DK2950786T3 (da) 2013-01-31 2020-02-17 Gilead Pharmasset Llc Kombinationsformulering af to antivirale forbindelser
WO2015132321A1 (en) * 2014-03-05 2015-09-11 Galenicum Health S.L. Stable pharmaceutical compositions of sofosbuvir
SI3524234T1 (sl) 2014-06-13 2021-05-31 Ratiopharm Gmbh Trdne oblike sofosbuvira
WO2015197549A1 (en) * 2014-06-23 2015-12-30 Sanovel Ilac Sanayi Ve Ticaret A.S. A novel pharmaceutical composition of sofosbuvir and ribavirin
US20170128482A1 (en) * 2014-06-23 2017-05-11 Sanovel Ilac Sanayi Ve Ticaret A.S. Modified release pharmaceutical compositions of sofosbuvir and ribavirin
EA201692507A1 (ru) * 2014-06-23 2017-04-28 Сановель Илач Санайи Ве Тиджарет А.Ш. Фармацевтические комбинации софосбувира и рибавирина
CN105267232A (zh) * 2014-06-30 2016-01-27 康普药业股份有限公司 一种用于治疗丙型肝炎的药物制剂及其制备方法
WO2016035006A1 (en) * 2014-09-01 2016-03-10 Dr. Reddy’S Laboratories Limited Novel nucleotide analogs, process for the preparation of sofosbuvir and its analogs, novel forms of sofosbuvir and solid dispersion of sofosbuvir
EP3203987A1 (en) * 2014-10-08 2017-08-16 Sandoz AG High drug load tablets comprising sofosbuvir
CN104546783A (zh) * 2014-12-12 2015-04-29 安徽一灵药业有限公司 一种索非布韦薄膜包衣片制剂及其制备方法
CN104622836B (zh) * 2014-12-23 2020-02-21 浙江华海药业股份有限公司 索非布韦包衣片剂及其制备方法
ES2892123T3 (es) 2014-12-26 2022-02-02 Univ Emory Derivados antivíricos de N4-hidroxicitidina
CN104586802B (zh) * 2015-02-02 2018-01-16 长春海悦药业股份有限公司 一种含有索菲布韦的药物组合物
WO2016156330A1 (en) * 2015-03-30 2016-10-06 Ratiopharm Gmbh Solid pharmaceutical composition comprising amorphous sofosbuvir and a phospholipid
CN104840964B (zh) * 2015-05-07 2018-01-16 南京正大天晴制药有限公司 一种稳定的索氟布韦药物组合物及其制备方法
CZ2015443A3 (cs) 2015-06-26 2017-01-04 Zentiva, K.S. Farmaceutická formulace sofosbuviru
CN104906062B (zh) * 2015-06-30 2018-05-25 浙江天顺生物科技有限公司 一种索非布韦的片剂及其制备方法
BR102017011025A2 (pt) 2016-06-02 2017-12-19 Gilead Pharmasset Llc Formulation of combination of three antiviral compounds
CA3033858A1 (en) 2016-08-19 2018-02-22 Sandoz Ag Sofosbuvir derivatives for the treatment of hepatitis c
CZ2016553A3 (cs) 2016-09-09 2018-03-21 Zentiva, K.S. Pevná farmaceutická dávková forma obsahující sofosbuvir
CN106667936B (zh) * 2016-12-31 2021-02-05 江苏科本药业有限公司 一种索非布韦片剂及其制备方法
CN106880642B (zh) * 2017-02-17 2019-08-06 杭州青玥医药科技有限公司 索氟布韦药物组合物及其制备方法
CN107041873B (zh) * 2017-02-17 2020-02-28 杭州青玥医药科技有限公司 索氟布韦包衣片剂的制备方法
GB2581936B (en) 2017-12-07 2021-02-10 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
KR20200043618A (ko) 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
CN110604726B (zh) * 2019-07-19 2022-06-07 株洲千金药业股份有限公司 一种索非布韦组合物及其应用
CN111072742B (zh) * 2019-12-23 2022-12-02 南京正大天晴制药有限公司 一种治疗丙肝药物的新晶型及其组合物
CN111973566A (zh) * 2020-07-23 2020-11-24 石药集团中奇制药技术（石家庄）有限公司 一种索磷布韦片

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
IL154306A0 (en) * 2003-02-05 2003-09-17 Rimonyx Pharmaceuticals Ltd Pharmaceutical compositions comprising thieno [2,3-c] pyridine derivatives and use thereof
US7816326B2 (en) * 2004-02-27 2010-10-19 Schering Corporation Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
WO2008106130A2 (en) * 2007-02-26 2008-09-04 Achillion Pharmaceuticals, Inc. Tertiary amine substituted peptides useful as inhibitors of hcv replication
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
WO2009038663A1 (en) 2007-09-14 2009-03-26 Schering Corporation Method of treating hepatitis c patients
DE102007052070A1 (de) * 2007-10-30 2009-05-07 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Candesartancilexetil
DE102008057284A1 (de) * 2008-11-14 2010-05-20 Ratiopharm Gmbh Tabletten enthaltend Lenalidomid und Adhäsionsverstärker
AU2009316472B2 (en) * 2008-11-20 2015-07-09 Achillion Pharmaceuticals, Inc. Cyclic carboxamide compounds and analogues thereof as of Hepatitis C virus
DE102009015702A1 (de) * 2009-03-31 2010-10-07 Ratiopharm Gmbh Tabletten enthaltend Dapoxetin und Trockenverarbeitungsverfahren zu deren Herstellung
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (zh) * 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
EP2467144A1 (en) * 2009-07-24 2012-06-27 ViroLogik GmbH Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
BR112012024884A2 (pt) * 2010-03-31 2016-10-18 Gilead Pharmasset Llc síntese estereosseletiva de ativos contendo fósforo
US20120107278A1 (en) 2010-10-29 2012-05-03 Pharmasset, Inc. Abbreviated hcv therapy for hcv infected patients with il28b c/c genotype

Also Published As

Publication number Publication date
ES2817886T3 (es) 2021-04-08
CN104039319A (zh) 2014-09-10
EP2785340B1 (en) 2020-07-15
NZ625532A (en) 2016-07-29
UY34474A (es) 2013-06-28
TWI566773B (zh) 2017-01-21
MD20140058A2 (en) 2014-11-30
BR112014012739A2 (pt) 2017-06-13
KR101560994B1 (ko) 2015-10-15
AU2012346217A1 (en) 2014-06-19
CN104039319B (zh) 2017-12-29
ECSP14005678A (es) 2015-12-31
JP2016053096A (ja) 2016-04-14
BR112014012739A8 (pt) 2017-06-20
CA2856529A1 (en) 2013-06-06
MD4430B1 (ro) 2016-08-31
HK1202268A1 (en) 2015-09-25
PH12014501133A1 (en) 2014-09-01
CO6970603A2 (es) 2014-06-13
CA2856529C (en) 2018-03-06
EP2785340A1 (en) 2014-10-08
KR20140108645A (ko) 2014-09-12
ZA201404061B (en) 2016-09-28
MX2014006373A (es) 2014-07-22
AU2012346217B2 (en) 2016-02-04
JP5899327B2 (ja) 2016-04-06
EA027296B1 (ru) 2017-07-31
EP3777867A1 (en) 2021-02-17
WO2013082003A1 (en) 2013-06-06
JP2014533733A (ja) 2014-12-15
PH12014501133B1 (en) 2014-09-01
EA201490903A1 (ru) 2014-11-28
MD4430C1 (ro) 2017-03-31
TW201325599A (zh) 2013-07-01
PE20141296A1 (es) 2014-10-08
AR089578A1 (es) 2014-09-03

Similar Documents

Publication Publication Date Title
SG11201402609RA (en) Compositions and methods for treating hepatitis c virus
HRP20181564T1 (hr) Pripravci i postupci za inhibiciju ekspresije gena virusa hepatitisa b
ZA201306720B (en) Hepatitis c virus inhibitors
IL229270B (en) Hepatitis c virus inhibitors
EP2768517A4 (en) HEPATITIS C-VIRUS HEMMER
HK1208364A1 (en) Method for treating hepatitis c virus infection using quercetin- containing compositions
EP2688592A4 (en) COMPOSITIONS AND METHODS FOR IMMUNIZATION AGAINST HEPATITIS C VIRUS
ZA201309356B (en) Hepatitis c virus inhibitors
HK1209319A1 (en) Methods for treating hepatitis c
HK1212332A1 (en) Hepatitis c virus inhibitors
EP2802353A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
EP2869821A4 (en) COMPOSITIONS AND METHODS FOR TREATING AND INHIBITING VIRAL INFECTIONS
EP2663327A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
HK1209320A1 (en) Methods for treating hepatitis c
ZA201207226B (en) Compositions and methods for treating viral diseases
SG11201402899TA (en) Methods and compositions for treating viral diseases
PT2838903T (pt) Métodos e composições para tratamento de infeções virais
IL232889A0 (en) Compounds and methods for treating hepatitis c virus
HK1199617A1 (en) Compositions and methods for treating viral diseases